An international multidisciplinary consensus statement on MAFLD and the risk of CVD
- PMID: 37204656
- PMCID: PMC10198034
- DOI: 10.1007/s12072-023-10543-8
An international multidisciplinary consensus statement on MAFLD and the risk of CVD
Abstract
Background: Fatty liver disease in the absence of excessive alcohol consumption is an increasingly common condition with a global prevalence of ~ 25-30% and is also associated with cardiovascular disease (CVD). Since systemic metabolic dysfunction underlies its pathogenesis, the term metabolic (dysfunction)-associated fatty liver disease (MAFLD) has been proposed for this condition. MAFLD is closely intertwined with obesity, type 2 diabetes mellitus and atherogenic dyslipidemia, which are established cardiovascular risk factors. Unlike CVD, which has received attention in the literature on fatty liver disease, the CVD risk associated with MAFLD is often underestimated, especially among Cardiologists.
Methods and results: A multidisciplinary panel of fifty-two international experts comprising Hepatologists, Endocrinologists, Diabetologists, Cardiologists and Family Physicians from six continents (Asia, Europe, North America, South America, Africa and Oceania) participated in a formal Delphi survey and developed consensus statements on the association between MAFLD and the risk of CVD. Statements were developed on different aspects of CVD risk, ranging from epidemiology to mechanisms, screening, and management.
Conculsions: The expert panel identified important clinical associations between MAFLD and the risk of CVD that could serve to increase awareness of the adverse metabolic and cardiovascular outcomes of MAFLD. Finally, the expert panel also suggests potential areas for future research.
Keywords: Cardiovascular disease; Consensus; Delphi survey; MAFLD; Metabolic (dysfunction)-associated fatty liver disease; Non-alcoholic fatty liver disease.
© 2023. Asian Pacific Association for the Study of the Liver.
Conflict of interest statement
George V Papatheodoridis: Advisor: Abbvie, Albireo, Amgen, Dicerna, Gilead, GlaxoSmithKline, Ipsen, Janssen, Novo Nordisk, Roche and Takeda; Lectures: Abbvie, Gilead, GlaxoSmithKline, Ipsen, Novo Nordisk, Sobi; Research grants: Abbvie, Gilead; Investigator in clinical trials: Abbvie, Astellas, Bayer, Eiger, Gilead, GlaxoSmithKline, Janssen, Merck Sharp & Dohme, Noorik, Novartis, Novo Nordisk, Regulus, Roche, Takeda. Giada Sebastiani: Speaker: Merck, Gilead, Abbvie, Novonordisk, Novartis and Pfizer; Advisory board member: Pfizer, Merck, Novonordisk, Gilead and Intercept; Unrestricted research funding: Theratecnologies Inc. Gregory Y. H. Lip: Consultant and speaker for BMS/Pfizer, Boehringer Ingelheim, Daiichi-Sankyo, Anthem. No fees are received personally. GYHL is co-principal investigator of the AFFIRMO project on multimorbidity in AF, which has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 899871. Jian-Gao Fan: Speaker, a consultant and an advisory for Sanofi, Abbott, EchoSens, Novartis, Hisky, Gilead, Allergan, Terns and MADAUS GMBH. John D. Ryan: None related to MAFLD. Consulting: Bond Biosciences, Pfizer, Gilead; Lectures: Kyowa kirin, Falk. Marat Fudim: Dr Fudim was supported by Bayer. He receives consulting fees from Bayer, Merck, NovoNordisk. Michael D. Shapiro: Research Grants (paid to my institution): AHA, NIH, Amgen, Novartis, Ionis, Esperion; Consultant: Ionis, Novartis, Regeneron; Scientific Advisory Boards: Amgen, Novartis, Precision Bioscience. Mindie H. Nguyen: Last 36 months: Research support: Pfizer, Enanta, Astra Zeneca, Innogen, Exact Science, CurveBio, Delfi Biotech, Gilead, Exact Sciences, Vir Biotech, Helio Health, National Cancer Institute, Glycotest, B.K. Kee Foundation. Consulting and/or Advisory Board: Intercept, Exact Science, Gilead, GSK, Eli Lilly, Laboratory of Advanced Medicine, Exelixis Research grants. Ming-Hua Zheng: Lectures: Hisky Medical. Philippe Gabriel Steg: Research grants: Amarin, Bayer, Sanofi, and Servier; Clinical Trials (Steering committee, CEC, DSMB): Amarin, AstraZeneca, Bayer, Bristol-Myers Squibb, Idorsia, Novartis, PhaseBio, Pfizer, Sanofi, Servier; Consulting or speaking: Amarin, Amgen, BMS/Myokardia, Merck, Novo-Nordisk, Regeneron; Senior Associate Editor at Circulation. Seung Up Kim: He has served as an advisory committee member Gilead Sciences, Bayer, Eisai, and Novo Nordisk. He is a speaker for Gilead Sciences, GSK, Bayer, Eisai, Abbvie, EchoSens, MSD, Eisai, Otsuka, and Bristol-Myers Squibb. He has also received a research grant from Abbvie and Bristol-Myers Squibb. Vincent Wai-Sun Wong: Consultancy: AbbVie, Boehringer Ingelheim, Echosens, Gilead Sciences, Intercept, Inventiva, Novo Nordisk, Pfizer, Sagimet Biosciences, TARGET PharmaSolutions; Lectures: Abbott, AbbVie, Gilead Sciences, Novo Nordisk; Research grants: Gilead Sciences; Stock: Co-founder of Illuminatio Medical Technology Limited. Wah Kheong Chan: Consultant or advisory board member for Roche, Abbvie, Boehringer Ingelheim and Novo Nordisk; speaker for Viatris and Hisky Medical. Yusuf Yilmaz: He has served as consultant to Cymabay, Zydus, Novo Nordisk, and Echosens. The other authors have no conflicts of interest to declare.
Figures
![Fig. 1](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/10198034/bin/12072_2023_10543_Fig1_HTML.gif)
![Fig. 2](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/10198034/bin/12072_2023_10543_Fig2_HTML.gif)
Similar articles
-
An international multidisciplinary consensus on pediatric metabolic dysfunction-associated fatty liver disease.Med. 2024 Jul 12;5(7):797-815.e2. doi: 10.1016/j.medj.2024.03.017. Epub 2024 Apr 26. Med. 2024. PMID: 38677287
-
Nonalcoholic fatty liver disease or metabolic dysfunction-associated fatty liver disease diagnoses and cardiovascular diseases: From epidemiology to drug approaches.Eur J Clin Invest. 2021 Jul;51(7):e13519. doi: 10.1111/eci.13519. Epub 2021 Mar 2. Eur J Clin Invest. 2021. PMID: 33583033 Review.
-
Metabolic Dysfunction-Associated Fatty Liver Disease Is Associated with the Risk of Incident Cardiovascular Disease: A Prospective Cohort Study in Xinjiang.Nutrients. 2022 Jun 7;14(12):2361. doi: 10.3390/nu14122361. Nutrients. 2022. PMID: 35745091 Free PMC article.
-
Taiwan Association for the Study of the Liver-Taiwan Society of Cardiology Taiwan position statement for the management of metabolic dysfunction- associated fatty liver disease and cardiovascular diseases.Clin Mol Hepatol. 2024 Jan;30(1):16-36. doi: 10.3350/cmh.2023.0315. Epub 2023 Oct 4. Clin Mol Hepatol. 2024. PMID: 37793641 Free PMC article. Review.
-
Malaysian Society of Gastroenterology and Hepatology consensus statement on metabolic dysfunction-associated fatty liver disease.J Gastroenterol Hepatol. 2022 May;37(5):795-811. doi: 10.1111/jgh.15787. Epub 2022 Feb 8. J Gastroenterol Hepatol. 2022. PMID: 35080048 Free PMC article. Review.
Cited by
-
Glycolipid Metabolic Disorders, Metainflammation, Oxidative Stress, and Cardiovascular Diseases: Unraveling Pathways.Biology (Basel). 2024 Jul 12;13(7):519. doi: 10.3390/biology13070519. Biology (Basel). 2024. PMID: 39056712 Free PMC article. Review.
-
Impact of metabolic phenotype and alcohol consumption on mortality risk in metabolic dysfunction-associated fatty liver disease: a population-based cohort study.Sci Rep. 2024 Jun 3;14(1):12663. doi: 10.1038/s41598-024-63453-6. Sci Rep. 2024. PMID: 38830939 Free PMC article.
-
The correlation between liver fibrosis and the 10-year estimated risk of cardiovascular disease in adults with metabolic-associated fatty liver disease: A cross-sectional study in Vietnam.Health Sci Rep. 2024 May 8;7(5):e2102. doi: 10.1002/hsr2.2102. eCollection 2024 May. Health Sci Rep. 2024. PMID: 38725561 Free PMC article.
-
Underlying Mechanisms behind the Brain-Gut-Liver Axis and Metabolic-Associated Fatty Liver Disease (MAFLD): An Update.Int J Mol Sci. 2024 Mar 26;25(7):3694. doi: 10.3390/ijms25073694. Int J Mol Sci. 2024. PMID: 38612504 Free PMC article. Review.
-
MAFLD as part of systemic metabolic dysregulation.Hepatol Int. 2024 Apr 9. doi: 10.1007/s12072-024-10660-y. Online ahead of print. Hepatol Int. 2024. PMID: 38594474
References
MeSH terms
LinkOut - more resources
Full Text Sources
Medical